If a drug has a time-dependent CKD-related alteration, what is a practical approach to determine the right dosing in CKD patients?

• A. Use fixed dosing for all CKD stages
• B. Increase the dose in early CKD stages
• C. Discontinue use in CKD
• D. Use PK modeling with covariates for renal function, simulate exposure across CKD stages, and adjust dose/interval accordingly

Answer: (D)

When a drug’s clearance is affected by kidney disease in a way that changes over time, the practical approach is to build a pharmacokinetic model that includes renal function as a covariate and then use simulations to predict exposure across CKD stages, adjusting dose and dosing interval accordingly. By tying clearance to measurable renal function (like eGFR or creatinine clearance) within a population PK framework, you can forecast how AUC, trough, and peak concentrations will change as CKD progresses or improves. Running simulations across the spectrum of CKD stages lets you see which dosing regimens maintain target exposure and safety, and you can tailor the dose or interval to each stage. This approach directly addresses the time-dependent nature of the impairment, unlike fixed dosing, which doesn’t account for evolving clearance, or a blanket discontinue strategy.